BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson’s Disease

SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson’s disease who are naïve to carbidopa/levodopa